Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04678336 · ClinicalTrials.gov registry record · Phase 1
CD123 Redirected T Cells for AML in Pediatric Subjects
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04678336: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT04678336 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04678336, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML).
Interventions
- BIOLOGICAL CART123 cells; cyclophosphamide; fludarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-04-02 |
| Est. Completion | 2025-05-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04678336
The ClinicalTrials.gov registry entry for NCT04678336 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CART123 cells; cyclophosphamide; fludarabine is the first listed.
NCT04678336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04678336 about?
NCT04678336 is a clinical study titled "CD123 Redirected T Cells for AML in Pediatric Subjects". Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (...
What is the current status of trial NCT04678336?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-04-02. Estimated completion is 2025-05-09.
What interventions are being tested in trial NCT04678336?
The interventions under investigation include: CART123 cells; cyclophosphamide; fludarabine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04678336?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.